The number of people using GLP-1 medications is rising, with over 10.8 million Americans prescribed them by 2024. We know people who take them; some of us take them. As a result, bariatric surgery rates have plummeted and continue to fall. Obesity care is undergoing a structural shift. GLP-1 receptor agonists are altering the referral funnel that historically fed bariatric surgery. When patient flow shifts in a high-risk surgical domain, malpractice exposure does not decline proportionally. It often re-concentrates.
With over 73% of US adults overweight or obese, the number of patients seeking weight-loss treatment will continue to rise. Medical professional liability insurers should understand the liability implications of the two common approaches, bariatric surgery and GLP-1 management.
Bariatrics: The Canary in The Coal Mine
Bariatric surgery offers a valuable case study for MPL insurers. It is a clinically effective yet structurally high‑risk surgical domain. It is also undergoing rapid change, as GLP‑1 receptor agonists are reshaping obesity treatment. This presents a classic dilemma for insurers: The law of large numbers is giving way to adverse selection among patients and to risk concentration among fewer providers.
The rapid decline in bariatric surgery also foretells a shift in surgical procedures and associated liability, as these dynamics emerge throughout healthcare:
- Substitution of technology or pharmacology for procedures, especially for lower-risk patients
- Declining procedural scope in historically high-risk specialties
- Provider exit and consolidation
- Increasing case-mix severity among remaining practitioners
How Do These Weight Loss Treatments Work?
Bariatric surgery:
- Bariatric surgery induces significant weight loss by reducing hunger and increasing satiety. Additional benefits include healthier food choices and sustained weight loss, which in turn support more regular exercise.
- Surgery may offer superior long-term outcomes for appropriately selected patients, typically those at the higher end of the BMI spectrum. Not surprisingly, the American Society for Metabolic and Bariatric Surgery (ASMBS) and hospitals with significant practices highlight these benefits. A recent large study found that, among patients with obesity and type 2 diabetes, metabolic surgery was associated with greater sustained weight loss, improved glycemic control, reduced medication dependence, and significantly lower mortality risk compared with GLP-1 therapy alone (ASMBS, 2026).
Weight loss medications:
- GLP-1 medications are proven to lower blood sugar and promote weight loss. Well-known brand names, including Ozempic, Trulicity, and Wegovy, are commonly used to treat type 2 diabetes or obesity. Clinical trials report 10% to 20% weight loss, often enough for those with lower BMIs to improve many health measures and reduce mortality risk (NIH, 2018). In some cases, patients achieve weight reductions comparable to those from bariatric surgery.
- Realistically, weight loss averages 6% to 12% because these medications must be taken indefinitely to maintain it, at considerable expense to patients and health insurers. Excluding those with type 2 diabetes, approximately two out of three overweight or obese patients discontinue GLP-1s, typically due to weight loss, high costs, and adverse events.
Bariatric Surgery Is a High‑Risk Specialty
The best national malpractice datasets consistently show that surgical specialties, as a group—particularly neurosurgery, cardiovascular/thoracic surgery, general surgery, orthopedics, and obstetrics—have the highest claim frequencies. Bariatric surgery is typically grouped with general and advanced laparoscopic surgery in national malpractice datasets. Although not isolated as a standalone category, it falls within the highest-risk surgical tier.
From a risk‑management standpoint, bariatric surgery presents a high‑severity, long‑tail risk profile that extends well beyond surgical errors. Perioperative complications (occurring before, during, and after the operation) include readmissions, nutritional deficiencies, weight regain, and pregnancy risks, all of which can increase malpractice exposure over time.
Bariatrics is not risky because of provider incompetence; it is risky because it is technically complex, performed on medically fragile patients, and highly sensitive to adverse selection as the patient population shrinks.
Are Declining Bariatric Surgery Rates Good News for MPL Insurers?
Our findings suggest otherwise. The rapid adoption of GLP-1 medication has led to a sharp decline in bariatric surgery over the past four years. This fundamental shift has also driven a decline in the number of bariatric surgeons, as providers exit and fewer surgeons enter the subspecialty.
The rapid adoption of medication diverts patients before they enter the surgical funnel, typically selecting for patients who are lower‑severity, earlier in disease progression, more risk‑averse or surgery‑hesitant, and still surgery‑eligible. The remaining surgical case mix deteriorates as the remaining patients are sicker, heavier, and more medically complex. Essentially, when lower‑severity patients shift toward pharmacotherapy, the remaining surgical population becomes more medically complex. Even if complication rates within each risk category remain stable, the overall expected loss per case can rise as case‑mix severity increases. In insurance terms, this adverse selection results in fewer operations but potentially higher risk per operation.
Worse still, surgery doesn't eliminate the risk of medications. When weight loss plateaus or reverses following bariatric surgery, many patients add GLP-1 medications, further complicating attribution of adverse outcomes and liability. As a side note, litigation following post-bariatric plastic surgery poses additional risks because patients may mistake body-contouring procedures for aesthetic plastic surgery, even though these procedures are far more complicated.
Weight-loss drugs also carry medical risks. Severe—but rare—side effects can include pancreatitis, medullary thyroid cancer, acute (sudden) kidney injury, and an increased risk of vision loss or blindness related to diabetes. However, these risks don't necessarily translate into MPL exposure. To date, most GLP-1–related litigation has focused on manufacturers in product-liability actions.
Provider-level malpractice exposure remains diffuse because of broad prescribing patterns across primary care and multiple specialties. Because provider risk is widely spread, concentration is not an issue. A large analysis of US prescriptions for four common GLP-1 drugs found that primary care providers wrote about 38%, nurse practitioners about 25%, and endocrinologists, cardiologists, OB/GYNs, etc., wrote the remaining prescriptions.
Bariatrics Illustrates Shifting Liability for Surgical Procedures
Adverse selection has broad implications for surgical liability: Risk does not decline linearly with volume. When volume declines in a specialty that relies on repetition and team‑based expertise, risk often re‑concentrates. Our longitudinal claims data show that bariatric volume is not declining evenly across providers. Instead, marginal programs and lower‑volume surgeons exit or reduce their scope of practice, while remaining providers increasingly handle more complex cases.
Bariatrics is especially sensitive to system‑level change:
- Low-frequency but high-severity adverse events
- Concentrated provider exposure
- Medically complex patient populations
A common mistake in healthcare governance is assuming that fewer procedures automatically mean lower exposure. From a malpractice and enterprise‑risk perspective, bariatric surgery is a classic example of risk concentration. As provider counts shrink:
- Surgical redundancy declines
- Team familiarity erodes
- Outlier performance becomes more consequential
- Adverse events represent a larger share of the remaining volume
The bottom line? As GLP-1 medications reshape obesity care, bariatric surgery becomes more concentrated, more specialized, and more sensitive to volume loss. Medical organizations that rely only on lagging indicators will recognize this shift only after losses materialize; medical liability insurers will recognize it only as claims are filed. Forewarned is forearmed.